(Q34327226)

1 August 2017

1 reference

title

Combination lipid-altering therapy: an emerging treatment paradigm for the 21st century (English)

1 reference

1 August 2017

Jacobson TA

1

1 reference

1 August 2017

1 September 2001

1 reference

Current Atherosclerosis Reports

1 August 2017

1 reference

1 August 2017

3

1 reference

1 August 2017

5

1 reference

1 August 2017

373-382

1 reference

https://scigraph.springernature.com/pub.10.1007/s11883-001-0075-y

1 August 2017

0 references

cites work

Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11883-001-0075-Y

Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia

21 January 2018

1 reference

12 December 2020

Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin.

1 reference

12 December 2020

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

1 reference

12 December 2020

Long-term efficacy with fluvastatin as monotherapy and combined with cholestyramine (a 156-week multicenter study). French-Dutch Fluvastatin Study Group

1 reference

12 December 2020

High-dose fluvastatin and bezafibrate combination treatment for heterozygous familial hypercholesterolemia.

1 reference

12 December 2020

Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group

1 reference

12 December 2020

Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience

1 reference

12 December 2020

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

1 reference

12 December 2020

Fluvastatin with and without niacin for hypercholesterolemia

1 reference

12 December 2020

Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia

1 reference

12 December 2020

Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidaemia in diabetic and non-diabetic patients.

1 reference

12 December 2020

Inadequate treatment with HMG-CoA reductase inhibitors by health care providers

1 reference

12 December 2020

Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia

1 reference

12 December 2020

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

1 reference

12 December 2020

Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy

1 reference

12 December 2020

Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men

1 reference

12 December 2020

Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia

1 reference

12 December 2020

Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia

1 reference

12 December 2020

Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil

1 reference

12 December 2020

Genetics of familial combined hyperlipidemia

1 reference

12 December 2020

Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders

1 reference

12 December 2020

Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination

1 reference

12 December 2020

Role of triglycerides in coronary artery disease: lessons from the Prospective Cardiovascular Münster Study

1 reference

12 December 2020

Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease

1 reference

12 December 2020

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

12 December 2020

Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage

1 reference

12 December 2020

HMG-CoA reductase inhibitors and myotoxicity

1 reference

12 December 2020

Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramine

1 reference

12 December 2020

Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia

1 reference

12 December 2020

Treatment of hyperlipidemia with combined niacin-statin regimens

1 reference

12 December 2020

Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia

1 reference

12 December 2020

Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control.

1 reference

12 December 2020

Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel

1 reference

12 December 2020

Fluvastatin in familial hypercholesterolemia: a cohort analysis of the response to combination treatment

1 reference

12 December 2020

Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients

1 reference

12 December 2020

Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts

1 reference

12 December 2020

Drug interactions of lipid-altering drugs

1 reference

12 December 2020

Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease

1 reference

12 December 2020

Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety

1 reference

12 December 2020

Demographics and cardiology, 1950-2050

1 reference

12 December 2020

HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles

1 reference

12 December 2020

Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up

1 reference

12 December 2020

Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation.

1 reference

12 December 2020

Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels

1 reference

12 December 2020

Changes in plasma apolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. European Fluvastatin Study Group

1 reference

12 December 2020

Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia

1 reference

12 December 2020

Efficacy and Tolerability of Low-dose Simvastatin and Niacin, Alone and in Combination, in Patients With Combined Hyperlipidemia: A Prospective Trial

1 reference

12 December 2020

Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study)

1 reference

12 December 2020

Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia

1 reference

12 December 2020

Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern

1 reference

12 December 2020

10.1007/S11883-001-0075-Y

Identifiers

DOI

1 reference

PubMed ID

11487448

Dimensions Publication ID

1 August 2017

0 references

1 reference

PubMed ID

11487448